World's Best Scientists 2026 revealed!
Suzanne R. Hayman

Suzanne R. Hayman

D-Index & Metrics

Medicine

D-Index
95
Citations
33882
World Ranking
10061
National Ranking
5180

Suzanne R. Hayman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Suzanne R. Hayman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 813 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Suzanne R. Hayman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Suzanne R. Hayman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Suzanne R. Hayman is affiliated with the Mayo Clinic in the United States and has an extensive publication record in the fields of medicine and biochemistry, genetics, and molecular biology. Their work predominantly focuses on hematology, molecular biology, oncology, genetics, and immunology.

The scientist has made significant contributions to multiple areas of study, including multiple myeloma research and treatments, amyloidosis diagnosis and treatment, protein degradation and inhibitors, CAR-T cell therapy, chronic lymphocytic leukemia research, peptidase inhibition and analysis, as well as myeloproliferative neoplasms diagnosis and treatment.

Frequent co-authors working alongside Suzanne R. Hayman include Prashant Kapoor, Rahma Warsame, Taxiarchis Kourelis, David Dingli, and Shaji Kumar. This collaboration network highlights a strong connection within the hematological oncology research community.

The scientist's frequent publication venues demonstrate a focus on high-impact journals related to blood diseases and oncology. These venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Cancer Journal
  • Journal of Clinical Oncology
  • Leukemia

Among their recent published papers are:

  • "Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response" (2020, Blood Cancer Journal)
  • "Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities" (2020, Blood Advances)
  • "Mortality trends in multiple myeloma after the introduction of novel therapies in the United States" (2021, Leukemia)
  • "A simple additive staging system for newly diagnosed multiple myeloma" (2022, Blood Cancer Journal)
  • "Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update" (2021, Mayo Clinic Proceedings)

Best Publications

  • Improved survival in multiple myeloma and the impact of novel therapies

    Shaji K. Kumar;S. Vincent Rajkumar;Angela Dispenzieri;Martha Q. Lacy

  • Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

    S K Kumar;A Dispenzieri;M Q Lacy;M A Gertz

  • Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

    Shaji Kumar;Angela Dispenzieri;Martha Q. Lacy;Suzanne R. Hayman

  • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

    S. Vincent Rajkumar;Suzanne R. Hayman;Martha Q. Lacy;Angela Dispenzieri

  • Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma

    S. Vincent Rajkumar;Suzanne Hayman;Morie A. Gertz;Angela Dispenzieri

  • Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

    Shaji K. Kumar;Joseph R. Mikhael;Francis K. Buadi;David Dingli

  • Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

    Martha Q. Lacy;Suzanne R. Hayman;Morie A. Gertz;Angela Dispenzieri

  • Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.

    S Kumar;A Dispenzieri;M Q Lacy;S R Hayman

  • The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.

    Angela Dispenzieri;Martha Q. Lacy;Steven R. Zeldenrust;Suzanne R. Hayman

  • Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component

    John A. Lust;Martha Q. Lacy;Steven R. Zeldenrust;Angela Dispenzieri

  • Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.

    Eli Muchtar;Morie A. Gertz;Shaji K. Kumar;Martha Q. Lacy

  • Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

    Angela Dispenzieri;Martha Q. Lacy;Jerry A. Katzmann;S. Vincent Rajkumar

  • Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma

    Martha Q. Lacy;Angela Dispenzieri;Morie A. Gertz;Philip R. Greipp

  • Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

    Angela Dispenzieri;Robert A. Kyle;Martha Q. Lacy;Terry M. Therneau

  • Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

    Martha Q. Lacy;Jacob B. Allred;Morie A. Gertz;Suzanne R. Hayman

  • Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.

    Shaji Kumar;Rafael Fonseca;Rhett P. Ketterling;Angela Dispenzieri

  • A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

    A K Stewart;P L Bergsagel;P R Greipp;A Dispenzieri

  • Hypertension in pregnancy: an emerging risk factor for cardiovascular disease

    Vesna D Garovic;Suzanne R Hayman

  • Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains

    N. Leung;M.A. Gertz;S.R. Zeldenrust;S.V. Rajkumar

  • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Commentary

    Michele Cavo;S. Vincent Rajkumar;Suzanne R. Hayman;Martha Q. Lacy

Frequent Co-Authors

Morie A. Gertz
Morie A. Gertz Mayo Clinic
Martha Q. Lacy
Martha Q. Lacy Mayo Clinic
Shaji Kumar
Shaji Kumar Mayo Clinic
Francis K. Buadi
Francis K. Buadi Mayo Clinic
David Dingli
David Dingli Mayo Clinic
Nelson Leung
Nelson Leung Mayo Clinic
Robert A. Kyle
Robert A. Kyle Mayo Clinic
John A. Lust
John A. Lust Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in healthcare but not sure if medical school is your only option? There are flexible online degrees that pave the way to rewarding medical careers. For those considering practical roles in patient care, nursing school online provides a convenient and cost-effective way to enter the nursing field while balancing life's demands.

If you already hold an RN license, consider advancing your education through one of the cheapest online bsn programs. Earning a BSN opens doors to higher-level nursing roles and increased earning potential.

Interested in leadership or research? online phd nursing programs enable experienced nurses to shape healthcare policy or teach the next generation.

Even if you don’t have a nursing background, there are online msn programs for non nurses. These programs offer fast-track entry into advanced nursing roles for career changers.

Each of these pathways offers flexible online options that can help you start or advance a meaningful healthcare career—without attending traditional on-campus programs.

Best Scientists Citing Suzanne R. Hayman

Trending Scientists

Recently Published Articles